Department of Radiology
Found 38 results
Filters: Keyword is Prostatic Neoplasms  [Clear All Filters]
2023
Subramanian K, Martinez J, Castellanos SHuicochea, Ivanidze J, Nagar H, Nicholson S, Youn T, Nauseef JT, Tagawa S, Osborne JR.  2023.  Complex implementation factors demonstrated when evaluating cost-effectiveness and monitoring racial disparities associated with [18F]DCFPyL PET/CT in prostate cancer men.. Sci Rep. 13(1):8321.
Yun H, Kim J, Gandhe A, Nelson B, Hu JC, Gulani V, Margolis D, Schackman BR, Jalali A.  2023.  Cost-Effectiveness of Annual Prostate MRI and Potential MRI-Guided Biopsy After Prostate-Specific Antigen Test Results.. JAMA Netw Open. 6(11):e2344856.
Kang Z, Margolis DJ, Wang S, Li Q, Song J, Wang L.  2023.  Management Strategy for Prostate Imaging Reporting and Data System Category 3 Lesions.. Curr Urol Rep. 24(12):561-570.
Machado CML, Skubal M, Haedicke K, Silva FP, Stater EP, Silva TLA de O, Costa ET, Masotti C, Otake AH, Andrade LNS et al..  2023.  Membrane-derived particles shed by PSMA-positive cells function as pro-angiogenic stimuli in tumors.. J Control Release. 364:312-325.
Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, Cho SY, Fanti S, Giesel FL, Goffin K et al..  2023.  PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.. Eur J Nucl Med Mol Imaging. 50(5):1466-1486.
Kim H, Kang SWon, Kim J-H, Nagar H, Sabuncu M, Margolis DJA, Kim CKyo.  2023.  The role of AI in prostate MRI quality and interpretation: Opportunities and challenges.. Eur J Radiol. 165:110887.
Rogers HJ, Singh S, Barnes A, Obuchowski NA, Margolis DJ, Malyarenko DI, Chenevert TL, Shukla-Dave A, Boss MA, Punwani S.  2023.  Test-retest repeatability of ADC in prostate using the multi b-Value VERDICT acquisition.. Eur J Radiol. 162:110782.
Subramanian K, Stangl-Kremser J, Sawoszczyk L, Avlonitis V, Gernerd A, Nixon K, Zgaljardic M, Tagawa S, Bander N, Osborne JR.  2023.  α-Labeling of J591, an Antibody Targeting Prostate-Specific Membrane Antigen: The Technique and Considerations from the First Dedicated Production Lab at an Academic Institution in the United States.. J Nucl Med Technol. 51(3):215-219.
2022
Lawhn-Heath C, Hope TA, Martinez J, Fung EK, Shin J, Seo Y, Flavell RR.  2022.  Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose.. Lancet Oncol. 23(2):e75-e87.
2020
Kelly JM, Ponnala S, Amor-Coarasa A, Zia NA, Nikolopoulou A, Williams C, Schlyer DJ, DiMagno SG, Donnelly PS, Babich JW.  2020.  Preclinical Evaluation of a High-Affinity Sarcophagine-Containing PSMA Ligand for Cu/Cu-Based Theranostics in Prostate Cancer.. Mol Pharm. 17(6):1954-1962.
Deh K, Zaman M, Vedvyas Y, Liu Z, Gillen KMcCabe, Malley PO', Bedretdinova D, Nguyen T, Lee R, Spincemaille P et al..  2020.  Validation of MRI quantitative susceptibility mapping of superparamagnetic iron oxide nanoparticles for hyperthermia applications in live subjects.. Sci Rep. 10(1):1171.
2019
Kelly JM, Amor-Coarasa A, Ponnala S, Nikolopoulou A, Williams C, DiMagno SG, Babich JW.  2019.  Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window.. J Nucl Med. 60(5):656-663.
Guo H, Kommidi H, Vedvyas Y, McCloskey JE, Zhang W, Chen N, Nurili F, Wu AP, Sayman HB, Akin O et al..  2019.  A Fluorescent, [F]-Positron-Emitting Agent for Imaging Prostate-Specific Membrane Antigen Allows Genetic Reporting in Adoptively Transferred, Genetically Modified Cells.. ACS Chem Biol. 14(7):1449-1459.
Kelly JM, Amor-Coarasa A, Ponnala S, Nikolopoulou A, Williams C, Thiele NA, Schlyer D, Wilson JJ, DiMagno SG, Babich JW.  2019.  A Single Dose of Ac-RPS-074 Induces a Complete Tumor Response in an LNCaP Xenograft Model.. J Nucl Med. 60(5):649-655.
2018
Kommidi H, Guo H, Nurili F, Vedvyas Y, Jin MM, McClure TD, Ehdaie B, Sayman HB, Akin O, Aras O et al..  2018.  F-Positron Emitting/Trimethine Cyanine-Fluorescent Contrast for Image-Guided Prostate Cancer Management.. J Med Chem. 61(9):4256-4262.
Patel N, Halpern JA, Kasabwala K, Cricco-Lizza E, Herman M, Margolis D, Xu C, Robinson BD, Wang Y, McClure T et al..  2018.  Multiple Regions of Interest on Multiparametric Magnetic Resonance Imaging are Not Associated with Increased Detection of Clinically Significant Prostate Cancer on Fusion Biopsy.. J Urol. 200(3):559-563.
Patel N, Cricco-Lizza E, Kasabwala K, Xu C, Robinson BD, Khani F, Wang Y, Margolis D, Hu JC.  2018.  The Role of Systematic and Targeted Biopsies in Light of Overlap on Magnetic Resonance Imaging Ultrasound Fusion Biopsy.. Eur Urol Oncol. 1(4):263-267.
Kelly J, Amor-Coarasa A, Ponnala S, Nikolopoulou A, Williams C, Schlyer D, Zhao Y, Kim D, Babich JW.  2018.  Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors.. Eur J Nucl Med Mol Imaging. 45(11):1841-1851.
2017
Kelly JM, Amor-Coarasa A, Nikolopoulou A, Wüstemann T, Barelli P, Kim D, Williams C, Zheng X, Bi C, Hu B et al..  2017.  Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer.. J Nucl Med. 58(9):1442-1449.
Durand M, Jain M, Robinson B, Aronowitz E, Douahy YEl, Leung R, Scherr DS, Ng A, Donzeau D, Amiel J et al..  2017.  Magnetic resonance microscopy may enable distinction between normal histomorphological features and prostate cancer in the resected prostate gland.. BJU Int. 119(3):414-423.
Kelly J, Amor-Coarasa A, Nikolopoulou A, Kim D, Williams C, Ponnala S, Babich JW.  2017.  Synthesis and pre-clinical evaluation of a new class of high-affinity F-labeled PSMA ligands for detection of prostate cancer by PET imaging.. Eur J Nucl Med Mol Imaging. 44(4):647-661.
2016
Pandit-Taskar N, O'Donoghue JA, Ruan S, Lyashchenko SK, Carrasquillo JA, Heller G, Martinez DF, Cheal SM, Lewis JS, Fleisher M et al..  2016.  First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.. J Nucl Med. 57(12):1858-1864.
Bowen RL, Butler T, Atwood CS.  2016.  Not All Androgen Deprivation Therapies Are Created Equal: Leuprolide and the Decreased Risk of Developing Alzheimer's Disease.. J Clin Oncol. 34(23):2800.
2015
Pandit-Taskar N, O'Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM, Beylergil V, Lefkowitz RA, Carrasquillo JA, Martinez DF, Fung AMak et al..  2015.  A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.. Clin Cancer Res. 21(23):5277-85.
2014
Doran MG, Watson PA, Cheal SM, Spratt DE, Wongvipat J, Steckler JM, Carrasquillo JA, Evans MJ, Lewis JS.  2014.  Annotating STEAP1 regulation in prostate cancer with 89Zr immuno-PET.. J Nucl Med. 55(12):2045-9.